title: Safety of Benazepril in 400 Azotemic and 110 Non-Azotemic Client-Owned Cats (2001-2012).
abstract: This retrospective study examined cats after initiation of benazepril therapy to determine the frequency of systemic hypotension or elevations in serum creatinine and/or potassium. Medical records review identified azotemic and non-azotemic cats prescribed benazepril. Blood pressure was recorded at the first available time after initiation of therapy. No cats experienced documented systolic systemic hypotension (<90 mmHg). Serum creatinine, and potassium when available, were recorded at baseline and in time windows after initiation of treatment: 1-30 days and 31-60 days. Blood chemistry results were screened for hyperkalemia (≥6.0 mEq/L). During the first 2 mo after starting benazepril therapy, there was a low incidence (3.7%) and clinically insignificant magnitude of hyperkalemia. Serum creatinine increases of greater than 30% from baseline were noted. This change was found in 11.0% of cats during the first 30 days of therapy and in 13.7% of cats from days 31-60 after initiation of therapy. The long-term survival of the cats that had >30% increases in creatinine from baseline was not statistically different from the survival of those that did not experience these increases, which suggests this finding may not be a reason to discontinue therapy. Benazepril appeared safe in a heterogeneous population of cats.
authors.affiliation: From Cat Specialist, Castle Rock, Colorado (J.O.L.); Alamo Feline Health Center, San Antonio, Texas (G.D.N.); Department of Pathobiology and Population Medicine, Mississippi State College of Veterinary Medicine, Starkville, Mississippi (C.L.H.); and Department of Veterinary Clinical Sciences, The Ohio State University, Columbus, Ohio (D.J.C.).
authors.forename: Jennifer O
authors.initials: JO
authors.lastname: Lavallee
authors.affiliation: From Cat Specialist, Castle Rock, Colorado (J.O.L.); Alamo Feline Health Center, San Antonio, Texas (G.D.N.); Department of Pathobiology and Population Medicine, Mississippi State College of Veterinary Medicine, Starkville, Mississippi (C.L.H.); and Department of Veterinary Clinical Sciences, The Ohio State University, Columbus, Ohio (D.J.C.).
authors.forename: Gary D
authors.initials: GD
authors.lastname: Norsworthy
authors.affiliation: From Cat Specialist, Castle Rock, Colorado (J.O.L.); Alamo Feline Health Center, San Antonio, Texas (G.D.N.); Department of Pathobiology and Population Medicine, Mississippi State College of Veterinary Medicine, Starkville, Mississippi (C.L.H.); and Department of Veterinary Clinical Sciences, The Ohio State University, Columbus, Ohio (D.J.C.).
authors.forename: Carla L
authors.initials: CL
authors.lastname: Huston
authors.affiliation: From Cat Specialist, Castle Rock, Colorado (J.O.L.); Alamo Feline Health Center, San Antonio, Texas (G.D.N.); Department of Pathobiology and Population Medicine, Mississippi State College of Veterinary Medicine, Starkville, Mississippi (C.L.H.); and Department of Veterinary Clinical Sciences, The Ohio State University, Columbus, Ohio (D.J.C.).
authors.forename: Dennis J
authors.initials: DJ
authors.lastname: Chew
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001552:Benzazepines / Q000008:administration & dosage / Q000009:adverse effects*; D001794:Blood Pressure / Q000187:drug effects; D016022:Case-Control Studies; D002371:Cat Diseases / Q000188:drug therapy*; D002415:Cats; D005260:Female; D006973:Hypertension / Q000188:drug therapy / Q000662:veterinary*; D008297:Male; D051437:Renal Insufficiency / Q000662:veterinary*; D012189:Retrospective Studies
chemical_list: D000959:Antihypertensive Agents; D001552:Benzazepines; C044946:benazepril